Recent research has revealed that cytokines related to the NF-κB pathway are significantly elevated in individuals with NMO during the acute and remission phases48, suggesting that this pathway may represent a potential therapeutic target for the disease. The gene discussed is NFKB1; the disease is neuromyelitis optica.